Skip to main content

Table 3 MCS and PCS summary scores for DR-TB patients and those enrolled in the comparison groups

From: The impact of adverse events on health-related quality of life among patients receiving treatment for drug-resistant tuberculosis in Johannesburg, South Africa

  Mental component summary (MCS) Physical component summary (PCS)
SF-36 scale$ (Norm-based scale) Mean SD Mean SD
DR-TB (all patients; n = 149) 38.3 12.9 50.4 9.1
Patient-reported adverse event
 No adverse event 42.2 13.0 52.8 8.2
 Patient-reported adverse event 32.1 9.9 46.5 9.1
HIV status
 HIV negative (n = 27) 41.4 11.6 50.9 8.7
 HIV positive on ART (n = 94) 38.7 12.9 51.2 8.5
 HIV positive not on ART (n = 22) 34.5 13.9 46.7 10.7
 HIV status unknown (n = 6) 32.7 12.5 49.0 11.6
Duration of DR-TB treatment
  ≤ 6 months (n = 66) 31.9 11.3 48.5 9.9
  > 6 months (n = 83) 42.9 12.0 52.6 8.0
DR-TB regimen
 Standard regimen (long- and short-course) (n = 107) 37.9 13.4 51.1 8.9
 Did not report an AE 41.4 13.6 53.2 8.2
 Self-reported AE 31.4 10.4 47.1 8.8
 Individualized regimen (long- and short-course) (n = 42) 39.3 11.6 48.7 9.4
 Did not report an AE 45.1 10.8 51.7 8.3
 Self-reported AE 33.4 9.3 45.6 9.7
Comparison groups
 HIV positive on ART with DS-TB (n = 18) 44.4 15.7 48.5 9.6
 HIV positive on ART no TB (n = 50) 43.3 11.5 54.8 7.3
 Healthy Adultsa (n = 40) 50.3 10.3 57.6 5.1
  1. aFrom published data (van Aswegen et al., 2011)
  2. $Using the 36-Item Medical Outcomes Short Form Health Survey (SF-36)